SEPTEMBER 15, 2025

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis announces major progress in preparing its OBA Phase 2 trial of BIO101 in muscle wasting associated with obesity. The Company via its subsidiary in Brazil has secured funding support from EMBRAPII (Empresa Brasileira de Pesquisa e Inovação Industrial) and entered into agreements with two of the most respected obesity medical research and clinical centers in Brazil: FARMAVAX-UFMG (Inovação de Fármacos e Vacinas, Federal University of Minas Gerais) and FMRP-USP (Faculty of Medicine of Ribeirão Preto, University of São Paulo). Strengthening the

Read the press release »

SEPTEMBER 11, 2025

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 3 SARA trial of BIO101, targeting age related sarcopenia. This trial is designed to be the first phase 3 ever conducted in sarcopenia, reflecting the medical need in rapidly aging populations worldwide. Phase 3 SARA Clinical Trial Design The SARA Phase 3 trial plan to recruit a total of 932 patients and Biophytis proposes to recruit sarcopenic patients mainly in Asia (China and Japan) and in Europe. These regions were selected both for

Read the press release »

SEPTEMBER 3, 2025

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity Biophytis announces that the European Medicines Agency (EMA) has issued a favorable outcome on Part I of its Clinical Trial Application (CTA) for the initiation of a Phase 2 clinical trial of BIO101 (20-hydroxyecdysone) in patients suffering from muscle wasting associated with obesity (OBA study). This milestone represents a crucial regulatory step in advancing Biophytis’ clinical development strategy within Europe. The favorable review of the scientific dossier (Part I) confirms the quality, safety, and preclinical/clinical data package supporting the initiation of the trial. Pending completion of Part

Read the press release »

SEPTEMBER 1st, 2025

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 2 OBA trial of BIO101, targeting muscle wasting associated with obesity. This new program underscores Biophytis’s ambition to broaden the potential of its lead candidate BIO101 into high-prevalence global indications, opening significant new value-creation opportunities for the Company and its shareholders. Phase 2 OBA Clinical Trial Design The OBA Phase 2 trial will be a randomized, double-blind, placebo-controlled study recruiting 164 patients across two key geographies, strategically selected to accelerate development: Brazil: 122

Read the press release »

AUGUST 28, 2025

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial Biophytis announced that both Part I (European Medicines Agency scientific review) and Part II (Belgian national ethical assessment) of its Clinical Trial Application (CTA) for a Phase 3 study in sarcopenia have been successfully reviewed and accepted. With these approvals, Biophytis is now authorized to initiate patient enrollment for the Phase 3 sarcopenia trial at selected sites in Belgium. The company will also collaborate with leading clinical centers across additional European Member States under the harmonized European framework. “We are delighted to achieve both EMA and

Read the press release »

AUGUST 5, 2025

Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million Biophytis announces the establishment of a non-dilutive bond financing line for a maximum amount of €1 million with Hexagon Capital Fund, with an initial subscription of €100,000. Fullscreen Mode

Read the press release »

JULY 30, 2025

Biophytis Joins Silver Innov’, an Incubator Dedicated to the Silver Economy Biophytis is relocating to Silver Innov, an incubator and business center specialized in innovation, healthcare, and aging. This move represents a key milestone in Biophytis’ strategic roadmap, reinforcing its presence within an ecosystem dedicated to the silver economy, healthy aging, and biopharmaceutical innovation. As of this July, Biophytis has moved into the Silver Innov’ premises in Ivry-sur-Seine, joining a dynamic community of companies focused on senior healthcare challenges. Silver Innov’ offers a flexible and connected working environment designed to foster synergies between academic, hospital, and industrial stakeholders, notably through

Read the press release »

JULY 16, 2025

Biophytis Wins Major Legal Victory Before the French Court of Cassation Biophytis announces a major legal victory. On July 9, 2025, the French Court of Cassation, the country’s highest judicial authority, issued a landmark ruling partially overturning the decision of the Paris Court of Appeal and ruling in favor of Biophytis in its legal dispute with Negma Group. Stanislas Veillet, CEO of Biophytis, stated: “This victory comes at a pivotal time for Biophytis. The decision of the Court of Cassation is a key milestone in defending the interests of Biophytis and its shareholders. It validates the company’s unwavering efforts and

Read the press release »

JULY 15, 2025

Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced a strategic partnership with Lynx Analytics, a pioneer in artificial intelligence solutions for life sciences. The collaboration aims to accelerate the discovery and development of novel small molecule drugs for the treatment of sarcopenia, a debilitating condition characterized by progressive loss of muscle mass and strength in old adults. Fullscreen Mode

Read the press release »

JULY 11, 2025

Biophytis Reports 2024 Financial Results and 2025 Outlook Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as possible. Continued partnership strategy to support the funding of clinical programs. Strengthening of the drug discovery platform through the integration of disruptive technologies. Biophytis announced its financial results for the year ended December 31, 2024, approved by its Board of Directors on July 9, 2025, and presented its strategic outlook. The Company also announces the resumption of trading of its shares on Euronext Growth Paris, effective at market open on July 11, 2025. Stanislas Veillet,

Read the press release »